Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-22
    E.g., 2018-02-22

Articles

8648 items
2:21 PM, Jan 23, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Pain In vitro and mouse studies suggest a poly(A) oligonucleotide-based PABPC1 inhibitor could help treat pain. The oligonucleotide consisted of a poly(A) RNA oligonucleotide containing 2’-O-methyl ribose nucleotides throughout its structure and phosphorothioate bonds at...
2:21 PM, Jan 23, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; breast cancer Cell culture and mouse studies suggest inhibiting SLC1A5 could help treat colorectal cancer and breast cancer. In four human colorectal cancer cell lines, an aminobutanoic acid-based SLC1A5 inhibitor inhibited viability with...
1:18 PM, Jan 23, 2018  |  BC Innovations | Distillery Therapeutics

Dermatology

INDICATION: Dermatitis Mouse studies identified nine S. aureus and host factors as targets for treatment of dermatitis associated with S. aureus infections. In primary mouse and human keratinocytes treated with supernatants from S. aureus cultures, knockout...
1:18 PM, Jan 23, 2018  |  BC Innovations | Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Multiple sclerosis (MS); pain Mouse studies suggest inhibiting CAMK2A could help treat MS, including MS-associated pain. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, knock-in of an autophosphorylation-deficient CAMK2A variant or intrathecal injection...
1:17 PM, Jan 23, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting SAA1 in cancer-associated fibroblasts could help treat pancreatic ductal adenocarcinoma (PDAC). In tumor samples from patients, cancer-associated fibroblast levels of SAA1 were higher than...
1:17 PM, Jan 23, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Liver cancer Cell culture and mouse studies suggest inhibiting CCNE1 and CCNE2 could help treat liver cancer. In human liver cancer cell lines, combined shRNA-mediated knockdown of CCNE1 and CCNE2 decreased proliferation and colony formation...
1:17 PM, Jan 23, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Lung cancer; ovarian cancer Cell culture and mouse studies suggest inhibiting USP13 could help treat lung and ovarian cancers. In samples from lung cancer patients, USP13 levels were higher in tumor samples than in adjacent...
1:14 PM, Jan 23, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Solid tumors Cell culture and mouse studies suggest combining Votrient pazopanib and a potassium channel inhibitor could help treat rhabdoid tumors. High throughput screening of a library of approved drugs in six human rhabdoid...
1:13 PM, Jan 23, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) In vitro, cell culture and mouse studies identified a peptide-based inhibitor of the MYB-CREBBP interaction that could help treat AML. The inhibitor consisted of a retro-inverso form of a MYB fragment...
1:13 PM, Jan 23, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Chronic myelogenous leukemia (CML); acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting protein PML could help treat CML and AML. In co-cultures of primary mouse mesenchymal stem cells (MSCs) and mouse CML...

Pages